Patents by Inventor Tatsushi Toyokuni

Tatsushi Toyokuni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8927969
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: January 6, 2015
    Assignee: Searete LLC
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Patent number: 8735985
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: May 27, 2014
    Assignee: The Invention Science Fund I, LLC
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Publication number: 20140077162
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Application
    Filed: September 18, 2013
    Publication date: March 20, 2014
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Patent number: 8563965
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: October 22, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Patent number: 8455981
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: June 4, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Patent number: 8426842
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: April 23, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Patent number: 8354323
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: January 15, 2013
    Assignee: Searete LLC
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Patent number: 8278643
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: October 2, 2012
    Assignee: Searete LLC
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Publication number: 20110186806
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Application
    Filed: May 7, 2010
    Publication date: August 4, 2011
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Publication number: 20110186807
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Application
    Filed: May 7, 2010
    Publication date: August 4, 2011
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Publication number: 20110186805
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Application
    Filed: May 7, 2010
    Publication date: August 4, 2011
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Publication number: 20110186818
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Application
    Filed: May 7, 2010
    Publication date: August 4, 2011
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Publication number: 20110186817
    Abstract: A graphene substrate is doped with one or more functional groups to form an electronic device.
    Type: Application
    Filed: February 2, 2010
    Publication date: August 4, 2011
    Inventors: Jeffrey A. Bowers, Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Clarence T. Tegreene, Tatsushi Toyokuni, Richard N. Zare
  • Patent number: 7329401
    Abstract: This invention provides novel cyclooxygenase-2 selective agents that are particularly useful as imaging probes in non-invasive imaging techniques, such as PET and SPECT. Preferred cyclooxygenase-2 selective agents inhibit cyclooxygenase-2 activity with greater potency and specificity than conventional cyclooxygenase-2 inhibitors. Other aspects of the invention include pharmaceutical compositions including the cyclooxygenase-2 selective agents as well as methods for detecting and/or inhibiting cyclooxygenase-2. These methods are particularly useful for diagnosing and treating disorders, such as inflammation, which is characterized by elevated cyclooxygenase-2 levels.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: February 12, 2008
    Assignee: The Regents of the University of California
    Inventors: Tatsushi Toyokuni, Nagichettiar Satyamurthy, Harvey R. Herschman, Michael E. Phelps, Jorge R. Barrio
  • Publication number: 20070286801
    Abstract: This invention provides novel cyclooxygenase-2 selective agents that are particularly useful as imaging probes in non-invasive imaging techniques, such as PET and SPECT. Preferred cyclooxygenase-2 selective agents inhibit cyclooxygenase-2 activity with greater potency and specificity than conventional cyclooxygenase-2 inhibitors. Other aspects of the invention include pharmaceutical compositions including the cyclooxygenase-2 selective agents as well as methods for detecting and/or inhibiting cyclooxygenase-2. These methods are particularly useful for diagnosing and treating disorders, such as inflammation, which is characterized by elevated cyclooxygenase-2 levels.
    Type: Application
    Filed: January 10, 2003
    Publication date: December 13, 2007
    Inventors: Tatsushi Toyokuni, Nagichettiar Satyamurthy, Harvey Herschman, Michael Phelps, Jorge Barrio
  • Publication number: 20050245479
    Abstract: Systematic chemical analysis of glycosphingolipid (GSL) fractions from large quantities of normal human neutrophils and HL60 cells failed to detect GSL's which are binding targets of selectin. A series of long-chain, unbranched polylactosamine GSL's with a terminally sialylated, internally polyfucosylated structure bind selectins.
    Type: Application
    Filed: December 4, 2003
    Publication date: November 3, 2005
    Inventors: Kazuko Handa, Mark Stroud, Steven Levery, Tatsushi Toyokuni, Sen-Itiroh Hakomori, Yu Song
  • Publication number: 20030186935
    Abstract: Systematic chemical analysis of glycosphingolipid (GSL) fractions from large quantities of normal human neutrophils and HL60 cells failed to detect GSL's containing an SLex structure. Instead, the binding target of E-selectin was revealed to be a series of long-chain, unbranched polylactosamine GSL's with a terminally sialylated, internally polyfucosylated structure, called, “myeloglycan”.
    Type: Application
    Filed: April 25, 2003
    Publication date: October 2, 2003
    Inventors: Kazuko Handa, Mark R. Stroud, Steven B. Levery, Tatsushi Toyokuni, Sen-Itiroh Hakomori
  • Publication number: 20030064956
    Abstract: A series of long chain, unbranched polylactosamine glycosphingolipids with terminally sialylated, internally polyfucosylated structures binds selectins.
    Type: Application
    Filed: February 19, 2002
    Publication date: April 3, 2003
    Inventors: Kazuko Handa, Mark R. Stroud, Steven Levery, Tatsushi Toyokuni, Sen-Itiroh Hakomori, Yu Song
  • Patent number: 5747048
    Abstract: A method of producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens comprising: (1) immunizing a host with a core structure of a mucin-type glycoprotein; (2) fusing splenocytes from said immunized host with myeloma cells to form hybridoma cells; (3) culturing said hybridoma cells on selective medium; (4) selecting hybridoma cells surviving step (3) that secrete antibody that binds to said core structure of a mucin-type glycoprotein; (5) cloning said selected hybridoma cells from step (4); (6) culturing said cloned hybridoma cells; and (7) recovering said antibody. Hybridomas and monoclonal antibodies produced by the above-described method. Methods of passive and active immunization employing the monoclonal antibodies and mucin-type glycoproteins or synthetic oligosaccharide-carrier conjugates.
    Type: Grant
    Filed: December 6, 1994
    Date of Patent: May 5, 1998
    Assignee: The Biomembrane Institute
    Inventors: Thomas J. Kjeldsen, Henrik Clausen, Anil Singhal, Tatsushi Toyokuni, Helio Takahashi, Sen-itiroh Hakomori
  • Patent number: 5660834
    Abstract: A vaccine and method to prevent growth and replication of cancer cells that express a core structure of a mucin-type glycoprotein is disclosed. The vaccine comprises: (a) a pharmaceutically effective amount of an antigen comprising a purified mucin-type glycoprotein or a chemically synthesized mucin-type glycoprotein carbohydrate determinant conjugated to a carrier peptide or macromolecule, wherein said mucin-type glycoprotein expresses or carries the core structure of a mucin-type glycoprotein expressed on said cancer cells; and (b) a pharmaceutically acceptable carrier including natural or synthetic adjuvants. The method comprises administering the above-described vaccine to a host. A medicament and method for treating cancer wherein the cancer cells express a core structure of a mucin-type glycoprotein is disclosed.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: August 26, 1997
    Assignee: The Biomembrane Institute
    Inventors: Thomas J. Kjeldsen, Henrik Clausen, Anil Singhal, Tatsushi Toyokuni, Helio K. Takahashi, Sen-Itiroh Hakomori